A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT06679946
·
clinicaltrials.gov ↗
PHASE3
Phase
ENROLLING_BY_INVITATION
Status
700
Enrollment
INDUSTRY
Sponsor class
Conditions
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Interventions
DRUG:
Vutrisiran
Sponsor
Alnylam Pharmaceuticals